These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 20944138

  • 1. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.
    Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K.
    Anticancer Res; 2010 Sep; 30(9):3565-71. PubMed ID: 20944138
    [Abstract] [Full Text] [Related]

  • 2. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, Micksche M, Berger W.
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [Abstract] [Full Text] [Related]

  • 3. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
    Zhang D, Putti TC.
    Exp Cell Res; 2010 Dec 10; 316(20):3522-31. PubMed ID: 20833165
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
    Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D.
    Mol Pharmacol; 2007 Jan 10; 71(1):333-43. PubMed ID: 17050806
    [Abstract] [Full Text] [Related]

  • 5. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, Cho R, Nishimura M, Saito Y.
    Eur J Haematol; 2007 Nov 10; 79(5):382-91. PubMed ID: 17903213
    [Abstract] [Full Text] [Related]

  • 6. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM, Pelkonen J, Mönkkönen J.
    Bone; 2009 Dec 10; 45(6):1153-60. PubMed ID: 19699819
    [Abstract] [Full Text] [Related]

  • 7. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
    Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S, Picci P.
    Cancer Lett; 2007 Jun 08; 250(2):194-205. PubMed ID: 17113707
    [Abstract] [Full Text] [Related]

  • 8. Lung cancer cell line sensitivity to Zoledronic acid is BAX-dependent.
    Aoyagi T, Morii T, Ohtsuka K, Ohnishi H, Tajima T, Yoshiyama A, Mochizuki K, Satomi K, Ichimura S.
    Anticancer Res; 2013 Dec 08; 33(12):5357-63. PubMed ID: 24324070
    [Abstract] [Full Text] [Related]

  • 9. Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer.
    Tsuruta M, Nishibori H, Hasegawa H, Ishii Y, Endo T, Kubota T, Kitajima M, Kitagawa Y.
    Oncol Rep; 2008 Nov 08; 20(5):1165-72. PubMed ID: 18949417
    [Abstract] [Full Text] [Related]

  • 10. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
    Ryu K, Murata H, Koto K, Horie N, Matsui T, Nishigaki Y, Sakabe T, Takeshita H, Itoi M, Kimura S, Ashihara E, Maekawa T, Fushiki S, Kubo T.
    Anticancer Res; 2010 Jul 08; 30(7):2713-20. PubMed ID: 20683003
    [Abstract] [Full Text] [Related]

  • 11. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
    Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F.
    Oncotarget; 2014 Sep 15; 5(17):7805-19. PubMed ID: 25138053
    [Abstract] [Full Text] [Related]

  • 12. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR.
    Yang YX, Xiao ZQ, Chen ZC, Zhang GY, Yi H, Zhang PF, Li JL, Zhu G.
    Proteomics; 2006 Mar 15; 6(6):2009-21. PubMed ID: 16525997
    [Abstract] [Full Text] [Related]

  • 13. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.
    Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D.
    J Cell Mol Med; 2008 Jun 15; 12(3):928-41. PubMed ID: 18494934
    [Abstract] [Full Text] [Related]

  • 14. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
    Yang C, Hornicek FJ, Wood KB, Schwab JH, Mankin H, Duan Z.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):607-14. PubMed ID: 19125251
    [Abstract] [Full Text] [Related]

  • 15. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.
    Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J, Takahashi K, Nagawa H.
    J Surg Res; 2009 Jan 15; 151(1):115-20. PubMed ID: 18619615
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of heat shock protein 27-mediated resistance to DNA damaging agents by a novel PKC delta-V5 heptapeptide.
    Kim EH, Lee HJ, Lee DH, Bae S, Soh JW, Jeoung D, Kim J, Cho CK, Lee YJ, Lee YS.
    Cancer Res; 2007 Jul 01; 67(13):6333-41. PubMed ID: 17616692
    [Abstract] [Full Text] [Related]

  • 17. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J, Mönkkönen H, Auriola S, Mönkkönen J.
    Biochem Pharmacol; 2010 Mar 01; 79(5):777-83. PubMed ID: 19819230
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S.
    BMC Cancer; 2006 Mar 15; 6():60. PubMed ID: 16539721
    [Abstract] [Full Text] [Related]

  • 19. [Heat-shock protein 27 linked to multi-drug resistance in human hepatic cancer cell lines].
    Peng SF, Fu L, Tan DM.
    Zhonghua Gan Zang Bing Za Zhi; 2007 May 15; 15(5):362-5. PubMed ID: 17524270
    [Abstract] [Full Text] [Related]

  • 20. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P.
    Oncogene; 2010 Apr 01; 29(13):1883-96. PubMed ID: 20101233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.